Considerations of of critical quality attributes in the analytical comparability assessment of biosimilar products
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Ohseok | - |
dc.contributor.author | Joung, Jeewon | - |
dc.contributor.author | Park, Younjoo | - |
dc.contributor.author | Kim, Chan Wha | - |
dc.contributor.author | Hong, Seung Hwa | - |
dc.date.accessioned | 2021-09-03T04:11:53Z | - |
dc.date.available | 2021-09-03T04:11:53Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-07 | - |
dc.identifier.issn | 1045-1056 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/82888 | - |
dc.description.abstract | Based on experience in clinical trial approvals and marketing authorizations for biosimilar products in Korea, we suggest principles for the analytical comparability assessment of biosimilar products with respect to regulatory considerations. The composition and manufacturing processes of biosimilar products can differ from those of the reference product depending on the information available for the reference product and the time of product development; however, the analytical characteristics of biosimilar products should be highly similar to those of the reference product. Although manufacturing an identical product in terms of the quality profile is nearly impossible due to the high molecular weight and complex structure of biological products, the developer of the biosimilar product should attempt to establish a quality level as similar to that of the reference product as possible. When comparing the similarity of quality attributes, the criticality of the quality attributes and the characteristics of orthogonal quality attributes need to be considered carefully. Based on the results from the analytical comparability assessment, the comparability results of non-clinical and clinical studies should be evaluated before claiming biosimilarity to the reference product. In this review, we focus on quality attribute evaluation based on our regulatory experience. (C) 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD | - |
dc.subject | C-TERMINAL LYSINE | - |
dc.subject | HAMSTER OVARY CELLS | - |
dc.subject | THERAPEUTIC ANTIBODIES | - |
dc.subject | GLYCOSYLATION | - |
dc.subject | PROTEIN | - |
dc.subject | IDENTIFICATION | - |
dc.subject | TEMPERATURE | - |
dc.subject | CLEARANCE | - |
dc.subject | VARIANTS | - |
dc.subject | CULTURE | - |
dc.title | Considerations of of critical quality attributes in the analytical comparability assessment of biosimilar products | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Chan Wha | - |
dc.identifier.doi | 10.1016/j.biologicals.2017.04.005 | - |
dc.identifier.scopusid | 2-s2.0-85019015284 | - |
dc.identifier.wosid | 000407535800013 | - |
dc.identifier.bibliographicCitation | BIOLOGICALS, v.48, pp.101 - 108 | - |
dc.relation.isPartOf | BIOLOGICALS | - |
dc.citation.title | BIOLOGICALS | - |
dc.citation.volume | 48 | - |
dc.citation.startPage | 101 | - |
dc.citation.endPage | 108 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | C-TERMINAL LYSINE | - |
dc.subject.keywordPlus | HAMSTER OVARY CELLS | - |
dc.subject.keywordPlus | THERAPEUTIC ANTIBODIES | - |
dc.subject.keywordPlus | GLYCOSYLATION | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | TEMPERATURE | - |
dc.subject.keywordPlus | CLEARANCE | - |
dc.subject.keywordPlus | VARIANTS | - |
dc.subject.keywordPlus | CULTURE | - |
dc.subject.keywordAuthor | Biosimilar product | - |
dc.subject.keywordAuthor | Monoclonal antibody | - |
dc.subject.keywordAuthor | Analytical comparability | - |
dc.subject.keywordAuthor | Biosimilarity | - |
dc.subject.keywordAuthor | Quality attribute | - |
dc.subject.keywordAuthor | Criticality | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.